Premium
Biocompatibility of components of a female controlled drug delivery system
Author(s) -
Warrier Bharat K.,
Kostoryz Elisabet,
Lee Chi H.
Publication year - 2004
Publication title -
journal of biomedical materials research part a
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.849
H-Index - 150
eISSN - 1552-4965
pISSN - 1549-3296
DOI - 10.1002/jbm.a.30111
Subject(s) - biocompatibility , hela , microbicide , viability assay , cytotoxicity , drug delivery , sodium dodecyl sulfate , microbiology and biotechnology , ethylenediaminetetraacetic acid , gel electrophoresis , in vitro , materials science , chemistry , biochemistry , biology , chelation , immunology , nanotechnology , human immunodeficiency virus (hiv) , metallurgy
A female controlled drug delivery system (FcDDS) containing sodium dodecyl sulfate as a microbicide, ethylenediaminetetraacetic acid (EDTA) as a synergistic microbicide, and lactic acid as a pH modulator was developed as an intravaginal barrier device against sexually transmitted diseases. The host response of the vagina to the FcDDS was evaluated through biocompatibility tests including cell viability, estrogenicity, and cytotoxicity assays on HeLa cervical cells and NIH:Ovcar‐3 ovarian cells. Gel electrophoresis and reverse transcriptase polymerase chain reaction assays on HeLa cervical cell lines were also performed to elucidate the effects of EDTA on the expression of particular proteins of interest. The results of the cell viability test showed no significant difference in viability of cells upon exposure to EDTA at concentrations less than 0.035% that was reported to exert spermicidal activity. EDTA at concentrations less than 0.035% did not cause any cytotoxicity. The results of reverse transcriptase polymerase chain reaction analysis revealed that EDTA induced the expression of a 67‐kDa protein in HeLa cells, which was identified as elastin binding protein (a part of the elastin receptor complex). This work has demonstrated that FcDDS containing EDTA is biocompatible and safe to be used as an intravaginal barrier device. © 2004 Wiley Periodicals, Inc. J Biomed Mater Res 71A: 209–216, 2004